Workflow
Mangoceuticals(MGRX)
icon
Search documents
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
Newsfilter· 2024-05-21 12:30
Formulations to be marketed as "Slim" and "Trim" as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide ("Slim") and Tirzepatide ("Trim") to ...
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
Newsfilter· 2024-05-16 20:40
Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies today announced that it has recently reported noteworthy growth in both revenue and customer acquisition in the first quarter ended March 31, 2024 as compared to the quarter ended March 31, 2023. Specifical ...
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
globenewswire.com· 2024-05-16 20:40
Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies today announced that it has recently reported noteworthy growth in both revenue and customer acquisition in the first quarter ended March 31, 2024 as compared to the quarter ended March 31, 2023. Specifical ...
Mangoceuticals(MGRX) - 2024 Q1 - Quarterly Report
2024-05-15 20:52
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41615 Mangoceuticals, Inc. (Exact name of Registrant as specified in its charter) | Texas | 87-3841292 | | --- | --- | | (State ...
Mangoceuticals(MGRX) - Prospectus(update)
2024-05-06 21:32
As filed with the Securities and Exchange Commission on May 6, 2024 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Registration No. 333-278888 Texas 8099 87-3841292 (I.R.S. Employer Identification Number) 15110 ...
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
Newsfilter· 2024-04-25 12:30
Provides MangoRx with entrance into the non-Rx based, nutraceutical product space for sales on both direct-to-consumer online platforms and through retail locations Dallas, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acqui ...
Mangoceuticals(MGRX) - Prospectus
2024-04-23 21:28
As filed with the Securities and Exchange Commission on April 23, 2024 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) Texas 8099 87-3841292 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15110 N. Dallas Parkw ...
Mangoceuticals(MGRX) - 2023 Q4 - Annual Report
2024-04-01 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41615 Mangoceuticals, Inc. (Exact name of registrant as specified in its charter) | Texas | | 87-3841292 | | --- | --- | --- | | (State or other jurisdiction of | | (I.R.S. Em ...
Mangoceuticals(MGRX) - Prospectus(update)
2023-12-12 22:14
As filed with the Securities and Exchange Commission on December 12, 2023. Registration No. 333-275993 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Texas 8099 87-3841292 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Num ...
Mangoceuticals(MGRX) - Prospectus
2023-12-11 22:29
As filed with the Securities and Exchange Commission on December 11, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Texas 8099 87-3841292 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15110 N. Dallas Parkway, Suite 600 Dallas ...